Skip to main content

Advertisement

SpringerLink
Log in

The similar survival benefits of stable disease and partial response to pemetrexed in previously treated non-small cell carcinoma patients

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

Pemetrexed is a recognized active agent for the second-line treatment for advanced non-small cell lung cancer (NSCLC). This study was undertaken to evaluate the clinical benefits of pemetrexed and to identify patient characteristics that predict response to pemetrexed.

Methods

We retrospectively reviewed the medical records of patients with histologically proven stage IIIB or IV NSCLC who were treated with pemetrexed after the failure of prior chemotherapy.

Results

The objective response rate for the 99 enrolled patients was 13.1% and 22 patients achieved stable disease (SD)—a disease control rate of 35.4%. Progression-free survival and overall survival (OS) were 1.8 months (95% CI, 1.32–2.28) and 7.6 months (95% CI, 6.23–8.97), respectively. The patients who achieved SD and pemetrexed-responders showed similar OSs (14.6 vs. 14.8 months, P = 0.55). However, a squamous cell carcinoma histology showed no significant OS difference between those that achieved disease control or progression (8.1 vs. 5.6 months, P = 0.07). Subgroup analysis of OS revealed that histology and response to first-line therapy predicted response to pemetrexed.

Conclusions

Pemetrexed has comparable survival benefits in NSCLC patients that show objective response or stable disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Ceppi P, Volante M, Saviozzi S et al (2006) Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 107(7):1589–1596

    Article  CAS  PubMed  Google Scholar 

  • D’Addario G, Felip E (2008) Non-small-cell lung cancer ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19(Suppl 2):ii39–ii40

    Article  PubMed  Google Scholar 

  • Govindan R, Page N, Morgensztern D et al (2006) Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24(28):4539–4544

    Article  PubMed  Google Scholar 

  • Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22(9):1589–1597

    Article  CAS  PubMed  Google Scholar 

  • Huang CL, Liu D, Nakano J et al (2007) E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer. Clin Cancer Res 13(23):6938–6946

    Article  CAS  PubMed  Google Scholar 

  • Jemal A, Siegel R, Ward E et al (2008) Cancer statistics 2008. CA Cancer J Clin 58(2):71–96

    Article  PubMed  Google Scholar 

  • Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24(14):2137–2150

    Article  PubMed  Google Scholar 

  • Lee HY, Ahn MJ, Park YH et al (2009) Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: a prospective, multicenter trial. Lung Cancer. doi:10.1016/j.lungcan.2009.02.008

  • National Comprehensive Cancer Network (NCCN) (2008) Clinical practice guidelines in oncology. Non-small cell lung cancer, vol 2, 2009. http://www.nccn.org. Accessed 28 July 2009

  • Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311(7010):899–909

    Google Scholar 

  • Paesmans M, Sculier JP, Libert P et al (1995) Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol 13(5):1221–1230

    CAS  PubMed  Google Scholar 

  • Ramalingam S, Belani CP (2004) State-of-the-art chemotherapy for advanced non-small cell lung cancer. Semin Oncol 31(1 Suppl 1):68–74

    Article  CAS  PubMed  Google Scholar 

  • Salon C, Merdzhanova G, Brambilla C, Brambilla E, Gazzeri S, Eymin B (2007) E2F–1, Skp2 and cyclin E oncoproteins are upregulated and directly correlated in high-grade neuroendocrine lung tumors. Oncogene 26(48):6927–6936

    Article  CAS  PubMed  Google Scholar 

  • Scagliotti GV, Parikh P, von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26(21):3543–3551

    Article  CAS  PubMed  Google Scholar 

  • Scagliotti G, Hanna N, Fossella F et al (2009) The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 14(3):253–263

    Article  CAS  PubMed  Google Scholar 

  • Schmid M, Sen M, Rosenbach MD, Carrera CJ, Friedman H, Carson DA (2000) A methylthioadenosine phosphorylase (MTAP) fusion transcript identifies a new gene on chromosome 9p21 that is frequently deleted in cancer. Oncogene 19(50):5747–5754

    Article  CAS  PubMed  Google Scholar 

  • Shih C, Habeck LL, Mendelsohn LG, Chen VJ, Schultz RM (1998) Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv Enzyme Regul 38:135–152

    Article  CAS  PubMed  Google Scholar 

  • Sigmond J, Backus HH, Wouters D, Temmink OH, Jansen G, Peters GJ (2003) Induction of resistance to the multitargeted antifolate pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 66(3):431–438

    Article  CAS  PubMed  Google Scholar 

  • Smit EF, Burgers SA, Biesma B et al (2009) Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 27(12):2038–2045

    Article  CAS  PubMed  Google Scholar 

  • Sowers R, Toguchida J, Qin J et al (2003) mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma. Mol Cancer Ther 2(6):535–541

    CAS  PubMed  Google Scholar 

  • Sun JM, Lee KW, Kim JH et al (2009) Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer. Jpn J Clin Oncol 39(1):27–32

    Article  PubMed  Google Scholar 

  • Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216

  • van den Bogaert DP, Pouw EM, van Wijhe G et al (2006) Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma. J Thorac Oncol 1(1):25–30

    Article  PubMed  Google Scholar 

  • Weiss GJ, Rosell R, Fossella F et al (2007) The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 18(3):453–460

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest statement

None.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Korea Cancer Center Hospital, 215-4, Gongneung-dong, Nowon-gu, Seoul, 139-706, Korea

    Hye-Ryoun Kim, Min Soo Kang, Im Il Na, Sung Hyeon Yang, Yoon Hee Choi, Hye Jin Kang, Cheol Hyeon Kim & Jae Cheol Lee

Authors
  1. Hye-Ryoun Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Min Soo Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Im Il Na
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sung Hyeon Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoon Hee Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hye Jin Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Cheol Hyeon Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jae Cheol Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jae Cheol Lee.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, HR., Kang, M.S., Na, I.I. et al. The similar survival benefits of stable disease and partial response to pemetrexed in previously treated non-small cell carcinoma patients. J Cancer Res Clin Oncol 136, 547–552 (2010). https://doi.org/10.1007/s00432-009-0687-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-009-0687-0

Keywords

Search

Navigation